Hypothesis

In aging neurons, IPOD‑like amyloid aggregates sequester phosphorylated RNA‑binding proteins (RBPs) such as TDP‑43, converting dangerous soluble oligomers into an inert, storage‑compatible state. Therapeutic disaggregation that dissolves these deposits without simultaneously enhancing clearance of the sequestered RBPs will increase cytoplasmic toxic oligomers and worsen neurodegeneration.

Mechanistic Rationale

The proteostasis network actively sorts damaged proteins into JUNQ (ubiquitinated, degradable) and IPOD (amyloid‑like) compartments using an intact cytoskeleton and HSPs [1][2]. IPOD deposits are not random garbage; they represent a thermodynamically favored sink that lowers the effective concentration of seeding‑competent oligomers [3]. Recent work shows that slowing aging via insulin signaling promotes larger, less toxic aggregates in C. elegans Alzheimer models [4], indicating that aggregate size correlates with reduced proteotoxicity. We propose that IPODs specifically envelop hyper‑phosphorylated RBPs, which otherwise drive stress granule persistence and synaptic failure. By sequestering these RBPs, the cell reduces their concentration below the threshold needed for pathological phase transition and oligomer propagation.

If lysosomal function declines, IPODs may mature into solid phases that resist autophagic clearance, but the initial sequestration remains protective. Disaggregation agents (e.g., small‑molecule HSP104 activators or antibodies) that dissolve IPODs will release the sequestered RBPs back into the cytosol. Unless lysosomal degradation or autophagy is concurrently upregulated, the liberated RBPs will re‑form toxic oligomers, exacerbating damage.

Predictions & Experimental Design

1. Increased IPOD colocalization with p‑TDP‑43 in aged mouse brains – Immunofluorescence will show higher Pearson’s coefficient between IPOD marker (e.g., Hsp104‑GFP) and p‑TDP‑43 in 24‑month vs. 3‑month mice.
2. Disaggregation elevates cytosolic p‑TDP‑43 oligomers – Treating aged tdp‑43‑GFP mice with an IPOD‑disaggregating compound (e.g., AR7) will increase SDS‑resistant p‑TDP‑43 oligomers measured by filter trap assay, while total tdp‑43‑GFP remains unchanged.
3. Worsened phenotype without lysosomal boost – Mice receiving disaggregant alone will display reduced spontaneous alternation in the Y‑maze and increased cortical neuronal loss versus vehicle. Co‑treatment with a lysosomal activator (e.g., TFEB overexpression via AAV) will prevent oligomer rise and rescue behavior.
4. Rescue by autophagy induction independent of disaggregation – Rapamycin treatment in aged mice will lower p‑TDP‑43 oligomers despite persistent IPODs, indicating that clearance, not dissolution, is key.

Potential Outcomes & Interpretation

• If disaggregation alone raises toxic oligomers and impairs cognition, the hypothesis is supported, suggesting that current amyloid‑busting strategies risk releasing sequestered RBPs.
• If disaggregation lowers oligomers and improves outcomes, the hypothesis is falsified, implying that IPODs are purely pathogenic or that released RBPs are rapidly degraded.
• If lysosomal activation rescues the disaggregant‑induced toxicity, it confirms that the dangerous step is the loss of clearance capacity post‑disaggregation, aligning with the SENS view that lysosomal failure, not aggregate presence, drives toxicity.

This framework reframes aggregation as a protective sequestration step and predicts that successful neurotherapeutics must pair aggregate remodeling with enhanced lysosomal or autophagic flux.